Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes

  • US 6,150,337 A
  • Filed: 09/18/1998
  • Issued: 11/21/2000
  • Est. Priority Date: 01/23/1996
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of inversely modulating Type 1 and Type 2 responses of lymphocytes contained within an environment by adding ribavirin to the lymphocytes in a concentration which increases the Type 1 response and suppresses the Type 2 response.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×